Abstract
The prophylactic efficacies of atovaquone (ATQ) alone and in combination with azithromycin, clarithromycin, rifabutin, proguanil, PS-15, trimethoprim, co-trimoxazole, or dapsone were investigated in a SCID mouse model of Pneumocystis carinii pneumonia (PCP). ATQ alone was shown to have a significant dose-related effect, and at 200 mg/kg of body weight per day administered orally, the efficacy of ATQ was comparable to that of Septrin (co-trimoxazole). Of the drugs investigated orally in combination with ATQ, only dapsone (25 mg/kg/day) and to a lesser extent PS-15 (5 mg/kg/day) had any noteworthy antipneumocystis activity (at the doses examined) when administered alone. ATQ drug combinations affected the prophylactic efficacy of a subcurative dosage of ATQ (50 mg/kg/day given orally) in the following ways: dapsone (25 mg/kg/day) or co-trimoxazole (25 mg of sulfamethoxazole plus 5 mg of trimethoprim per kg/day) had no significant effect on ATQ, azithromycin (200 mg/kg/day) or clarithromycin (200 mg/kg/day) had a slight additive effect with ATQ, trimethoprim (100 mg/kg/day) or PS-15 (5 mg/kg/day) had an additive effect with ATQ, and proguanil (25 mg/kg/day) or rifabutin (200 mg/kg/day) had a marked synergistic effect on ATQ. The last result was particularly noteworthy as neither proguanil nor rifabutin was effective against PCP when administered alone. None of the drugs examined antagonized the prophylactic activity of ATQ in experimental PCP in SCID mice. The results suggest that clinical trials of ATQ with synergistic drug combinations may now be justified, particularly if such drug combinations improve ATQ's efficacy and broaden its spectrum of activity.
Full Text
The Full Text of this article is available as a PDF (177.2 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Araujo F. G., Lin T., Remington J. S. The activity of atovaquone (566C80) in murine toxoplasmosis is markedly augmented when used in combination with pyrimethamine or sulfadiazine. J Infect Dis. 1993 Feb;167(2):494–497. doi: 10.1093/infdis/167.2.494. [DOI] [PubMed] [Google Scholar]
- Araujo F. G., Slifer T., Remington J. S. Rifabutin is active in murine models of toxoplasmosis. Antimicrob Agents Chemother. 1994 Mar;38(3):570–575. doi: 10.1128/aac.38.3.570. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Comley J. C., Mullin R. J., Wolfe L. A., Hanlon M. H., Ferone R. Microculture screening assay for primary in vitro evaluation of drugs against Pneumocystis carinii. Antimicrob Agents Chemother. 1991 Oct;35(10):1965–1974. doi: 10.1128/aac.35.10.1965. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Comley J. C., Sterling A. M. Artificial infections of Pneumocystis carinii in the SCID mouse and their use in the in vivo evaluation of antipneumocystis drugs. J Eukaryot Microbiol. 1994 Nov-Dec;41(6):540–546. doi: 10.1111/j.1550-7408.1994.tb01514.x. [DOI] [PubMed] [Google Scholar]
- Falloon J., Kovacs J., Hughes W., O'Neill D., Polis M., Davey R. T., Jr, Rogers M., LaFon S., Feuerstein I., Lancaster D. A preliminary evaluation of 566C80 for the treatment of Pneumocystis pneumonia in patients with the acquired immunodeficiency syndrome. N Engl J Med. 1991 Nov 28;325(22):1534–1538. doi: 10.1056/NEJM199111283252202. [DOI] [PubMed] [Google Scholar]
- Hughes W. T., Gray V. L., Gutteridge W. E., Latter V. S., Pudney M. Efficacy of a hydroxynaphthoquinone, 566C80, in experimental Pneumocystis carinii pneumonitis. Antimicrob Agents Chemother. 1990 Feb;34(2):225–228. doi: 10.1128/aac.34.2.225. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hughes W. T., Jacobus D. P., Canfield C., Killmar J. Anti-Pneumocystis carinii activity of PS-15, a new biguanide folate antagonist. Antimicrob Agents Chemother. 1993 Jul;37(7):1417–1419. doi: 10.1128/aac.37.7.1417. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hughes W. T. Macrolide-antifol synergism in anti-Pneumocystis carinii therapeutics. J Protozool. 1991 Nov-Dec;38(6):160S–160S. [PubMed] [Google Scholar]
- Hughes W., Leoung G., Kramer F., Bozzette S. A., Safrin S., Frame P., Clumeck N., Masur H., Lancaster D., Chan C. Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS. N Engl J Med. 1993 May 27;328(21):1521–1527. doi: 10.1056/NEJM199305273282103. [DOI] [PubMed] [Google Scholar]
- Romand S., Pudney M., Derouin F. In vitro and in vivo activities of the hydroxynaphthoquinone atovaquone alone or combined with pyrimethamine, sulfadiazine, clarithromycin, or minocycline against Toxoplasma gondii. Antimicrob Agents Chemother. 1993 Nov;37(11):2371–2378. doi: 10.1128/aac.37.11.2371. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Walzer P. D., Foy J., Steele P., White M. Synergistic combinations of Ro 11-8958 and other dihydrofolate reductase inhibitors with sulfamethoxazole and dapsone for therapy of experimental pneumocystosis. Antimicrob Agents Chemother. 1993 Jul;37(7):1436–1443. doi: 10.1128/aac.37.7.1436. [DOI] [PMC free article] [PubMed] [Google Scholar]